Skip to main content
OpenTrials
Completed

NCT Number: NCT04222374

Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)

In the last decade, investigators from the Department of Cancer Epidemiology and Genetics (National Cancer Institute, USA) have conducted genome-wide association (GWAS) studies of renal cell carcinoma.

Dr. Mark PURDUE and Dr. Stephen CAHNOCK (Department of Epidemiology of Cancer and Genetics, NCI) propose to expand their genome-wide association study (Expanded GWAS) by genotyping approximately 10,000 additional cases of kidney cancer patients, in collaboration with US institutions, South-American and European.

This study describes the participation of the French Kidney Cancer Research Network (UroCCR) in the Expanded GWAS research, under the coordination of Professor BERNHARD (Bordeaux University Hospital).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Cancer Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Universitaire de Bordeaux

Talence, 33400, France

About this study

The aim of the Expanded GWAS study is to better understand the role of common genetic variants in susceptibility to renal cell carcinoma (RCC).

The participation of the French UroCCR network consists in completing the bio-collection of the UroCCR cohort by preserving constitutional DNA and to provide DNA samples to the US NCI team.

This will increase the number of samples for meta-analysis and contribute to better identify clear cell kidney cancer susceptibility loci.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18,
  • Confirmed cases of renal cell carcinoma (any RCC histology) of European or African origin,
  • Patients included in the UroCCR study,
  • Free, informed, written and signed consent by the participant and the investigator (at the latest on the day of inclusion and before any investigation required by the research) for specific blood collection for the purpose of DNA extraction,
  • Programmed or ongoing management for kidney tumor,
  • Constitutional DNA available (whole blood) for selected cases,
  • Affiliated person or beneficiary of a social security scheme.

Exclusion criteria

  • Patients below 18,
  • Refusal of consent or participation.

Treatment and study plan

Intervention in the UroCCR sites

Procedure
  • Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)
  • DNA extraction:
  • For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:
  • 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,
  • 1 aliquot for the UroCCR biobank.
  • For patients from other UroCCR centers, only 1 aliquot will be constituted:
  • 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.
  • Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux.

Intervention in the CRB of Bordeaux University Hospital

Procedure
  • Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.
  • Overall packing of GWAS samples for shipment to the NCI.
  • Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study.

Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital

Procedure

Transfer of the data associated with the samples to the NCI.

Subsequent intervention at the NCI (for information)

Procedure
  • Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.
  • GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples.

Primary outcomes

  1. Identification of new clear cell Renal Cell Carcinoma (ccRCC) risk loci

    Time frame: Inclusion Visit

    From the DNA sample collected at inclusion visit, and the derived Single Nucleotide Polymorphisms (SNPs) genotype data:

    Association between evaluated genetic variants (SNPs) and renal cell carcinoma will be statistically determined if the p-value is found to be close to or lower than the Genome-wide significance threshold (p <5*10-8).

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC) (Uro-DNA - GWAS)

Acronym: Uro-DNA - GWAS

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jan 10, 2020
Registry last updated
Jul 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.